{"id":6926,"date":"2025-05-22T12:13:59","date_gmt":"2025-05-22T09:13:59","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=6926"},"modified":"2025-05-22T12:13:59","modified_gmt":"2025-05-22T09:13:59","slug":"at-the-acc-25-scientific-session-dr-anna-bortnick-presented-findings-from-the-host-br-trial-which-evaluated-the-optimal-duration-of-dual-antiplatelet-therapy-dapt-after-percutaneous-coronary-inte","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/at-the-acc-25-scientific-session-dr-anna-bortnick-presented-findings-from-the-host-br-trial-which-evaluated-the-optimal-duration-of-dual-antiplatelet-therapy-dapt-after-percutaneous-coronary-inte\/","title":{"rendered":"At the ACC.25 Scientific Session, Dr. Anna Bortnick presented findings from the HOST-BR trial, which evaluated the optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) in patients with varying bleeding risks."},"content":{"rendered":"
At the ACC.25 Scientific Session, Dr. Anna Bortnick presented findings from the HOST-BR trial, which evaluated the optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) in patients with varying bleeding risks.<\/div>\n
<\/div>\n
Key Findings from the HOST-BR Trial:<\/div>\n
1. Study Design:<\/span><\/div>\n
\u2022 A multicenter, randomized, open-label trial conducted in South Korea.<\/span><\/div>\n
\u2022 Included 4,897 patients undergoing PCI with drug-eluting stents.<\/span><\/div>\n
\u2022 Participants were stratified into high bleeding risk (HBR) and low bleeding risk (LBR) groups based on ARC-HBR criteria.<\/span><\/div>\n
\u2022 HBR patients were randomized to receive either 1-month or 3-month DAPT.<\/span><\/div>\n
\u2022 LBR patients were randomized to receive either 3-month or 12-month DAPT.\u00a0\u00a0<\/span><\/div>\n
2. Primary Endpoints:<\/span><\/div>\n
\u2022 Net Adverse Clinical Events (NACE): composite of all-cause mortality, myocardial infarction (MI), stent thrombosis, stroke, or major bleeding.<\/span><\/div>\n
\u2022 Major Adverse Cardiac and Cerebral Events (MACCE): composite of cardiovascular death, MI, stent thrombosis, or ischemic stroke.<\/span><\/div>\n
\u2022 Bleeding events classified as BARC type 2, 3, or 5.\u00a0\u00a0<\/span><\/div>\n
3. Results in High Bleeding Risk (HBR) Patients:<\/span><\/div>\n
\u2022 3-month DAPT resulted in a lower incidence of NACE (14.0%) compared to 1-month DAPT (18.4%).<\/span><\/div>\n
\u2022 MACCE rates were also lower with 3-month DAPT (5.8%) versus 1-month DAPT (9.8%).<\/span><\/div>\n
\u2022 No significant difference in bleeding events between the two durations.\u00a0<\/span><\/div>\n
4. Results in Low Bleeding Risk (LBR) Patients:<\/span><\/div>\n
\u2022 3-month DAPT was non-inferior to 12-month DAPT concerning NACE (14.0% vs. 18.4%) and MACCE.<\/span><\/div>\n
\u2022 Significantly lower bleeding rates observed with 3-month DAPT (7.4%) compared to 12-month DAPT (11.7%).\u00a0<\/span><\/div>\n
<\/div>\n
Conclusion:<\/div>\n
The HOST-BR trial suggests that a 3-month DAPT regimen post-PCI may offer an optimal balance between reducing ischemic events and minimizing bleeding risks in both high and low bleeding risk patients.<\/div>\n
<\/div>\n
Source:<\/div>\n
\u2022 ACC.org: HOST-BR: Optimal DAPT Duration in Patients With High and Low Bleeding Risk?<\/span><\/div>\n","protected":false},"excerpt":{"rendered":"

At the ACC.25 Scientific Session, Dr. Anna Bortnick presented findings from the HOST-BR trial, which evaluated the optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) in patients with varying bleeding risks. Key Findings from the HOST-BR Trial: 1. Study Design: \u2022 A multicenter, randomized, open-label trial conducted in South Korea. \u2022 […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-6926","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/6926","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=6926"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/6926\/revisions"}],"predecessor-version":[{"id":6927,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/6926\/revisions\/6927"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=6926"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=6926"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=6926"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}